Lonza has completed its planned expansion of the bioconjugation facility in Visp (CH). The expansion includes two new manufacturing suites and supporting infrastructure to accommodate a wider range of customers, including companies entering clinical development. The investment improves Lonza's capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the increasing market demand for bioconjugates.
The new suites are part of Lonza's ongoing investments in Visp (CH) that include mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These investments aim to provide a flexible solution for customers of all sizes and help them navigate the complexities of the bioconjugation supply chain. In addition, the expansion includes an increase in process and analytical development and quality control capacity to support future portfolio growth. Stefan Egli, Vice President and Head of Bioconjugates at Lonza, said, "The opening of the new bioconjugate manufacturing suites in Visp (CH) demonstrates our commitment to continuously enhancing our offering and expertise to meet the expected market and customer needs. Our bioconjugation services, combined with our small molecule and biologics drug substance and drug product manufacturing, can support projects from early phase through to late-stage and commercial programs."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!